A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Prior to its transfer and sale during 2024 of the various assets described below, Arcadia was a producer and marketer of innovative, plant-based products. Arcadia sought to be a leader in science-based approaches to developing high value crop improvements, primarily in wheat which it commercialized through the sales of seed, grain, food ingredients and products, and through trait licensing and royalty agreements. The acquisition of the assets of Live Zola, LLC (“Zola”) in May 2021 added coconut water to Arcadia’s portfolio of products. In May 2021, Arcadia’s wholly owned subsidiary Arcadia Wellness, LLC (“Arcadia Wellness”), acquired the businesses of Eko Holdings, LLC, Lief, LLC.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 5.2M | 5.0M | - | 7.4M | 6.8M | 8.0M |
| Net Income | -5.1M | -7.0M | -14M | - | - | -4.7M |
| EPS | $-3.72 | $-5.17 | $-11.29 | $-25.65 | $-27.56 | $-0.47 |
| Free Cash Flow | -6.1M | -9.6M | -15M | -14M | -27M | -33M |
| ROIC | -31.3% | -46.3% | -37.5% | - | - | -15.6% |
| Gross Margin | 37.8% | 41.3% | - | 17.8% | -28.4% | 35.3% |
| Debt/Equity | 0.00 | 1.17 | 0.55 | 0.38 | 0.07 | 0.12 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -3.4M | -3.6M | -6.1M | -14M | -36M | -13M |
| Operating Margin | -65.8% | -72.3% | - | -188.8% | -524.0% | -159.0% |
| ROE | -93.1% | -73.8% | -82.5% | - | - | -26.3% |
| Shares Outstanding | 1M | 1M | 1M | 1M | 1M | 10M |
Arcadia Biosciences, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 16.5%. At current prices, the estimated annualized return to fair value is -3.3%.
Arcadia Biosciences, Inc. (RKDA) has a 5-year average return on invested capital (ROIC) of -33.2%. This is below average and may indicate limited pricing power.
Arcadia Biosciences, Inc. (RKDA) has a market capitalization of $2M. It is classified as a small-cap stock.
Arcadia Biosciences, Inc. (RKDA) does not currently pay a regular dividend.
Arcadia Biosciences, Inc. (RKDA) operates in the Crude Petroleum & Natural Gas industry, within the Energy sector.
Arcadia Biosciences, Inc. (RKDA) reported annual revenue of $5 million in its most recent fiscal year, based on SEC EDGAR filings.
Arcadia Biosciences, Inc. (RKDA) has a net profit margin of -139.5%. The company is currently unprofitable.
Arcadia Biosciences, Inc. (RKDA) generated $-10 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Arcadia Biosciences, Inc. (RKDA) has a debt-to-equity ratio of 1.17. This indicates moderate leverage.
Arcadia Biosciences, Inc. (RKDA) reported earnings per share (EPS) of $-5.17 in its most recent fiscal year.
Arcadia Biosciences, Inc. (RKDA) has a return on equity (ROE) of -73.8%. A negative ROE may indicate losses or negative equity.
Arcadia Biosciences, Inc. (RKDA) has a 5-year average gross margin of 16.5%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 11 years of financial data for Arcadia Biosciences, Inc. (RKDA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Arcadia Biosciences, Inc. (RKDA) has a book value per share of $4.57, based on its most recent annual SEC filing.